242 related articles for article (PubMed ID: 16533873)
1. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Kollmannsberger C; Schittenhelm M; Honecker F; Tillner J; Weber D; Oechsle K; Kanz L; Bokemeyer C
Ann Oncol; 2006 Jun; 17(6):1007-13. PubMed ID: 16533873
[TBL] [Abstract][Full Text] [Related]
2. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Hartmann JT; Kollmannsberger C; Cascorbi I; Mayer F; Schittenhelm MM; Heeger S; Bokemeyer C
Invest New Drugs; 2013 Jun; 31(3):661-8. PubMed ID: 22832803
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.
Schiller JH; von Pawel J; Schütt P; Ansari RH; Thomas M; Saleh M; McCroskey RD; Pfeifer W; Marsland TA; Kloecker GH; Sebastian M; Pirker R; Kurek R; Beadman C; Socinski MA
J Thorac Oncol; 2010 Dec; 5(12):1977-85. PubMed ID: 20978446
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.
Schittenhelm MM; Kollmannsberger C; Oechsle K; Harlow A; Morich J; Honecker F; Kurek R; Störkel S; Kanz L; Corless CL; Wong KK; Bokemeyer C; Heinrich MC
Mol Cancer Ther; 2009 Mar; 8(3):481-9. PubMed ID: 19276157
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab.
Socinski MA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4597-601. PubMed ID: 17671148
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Rao S; Starling N; Cunningham D; Benson M; Wotherspoon A; Lüpfert C; Kurek R; Oates J; Baselga J; Hill A
Br J Cancer; 2008 Sep; 99(6):868-74. PubMed ID: 19238629
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.
Graeven U; Kremer B; Südhoff T; Killing B; Rojo F; Weber D; Tillner J; Unal C; Schmiegel W
Br J Cancer; 2006 May; 94(9):1293-9. PubMed ID: 16622465
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J
J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
[TBL] [Abstract][Full Text] [Related]
11. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
12. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
Socinski MA; Saleh MN; Trent DF; Dobbs TW; Zehngebot LM; Levine MA; Bordoni R; Stella PJ
Ann Oncol; 2009 Jun; 20(6):1068-73. PubMed ID: 19188136
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.
Trarbach T; Przyborek M; Schleucher N; Heeger S; Lüpfert C; Vanhoefer U
Invest New Drugs; 2013 Jun; 31(3):642-52. PubMed ID: 22763610
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
18. EGFR-directed monoclonal antibodies in non-small cell lung cancer.
Pirker R
Target Oncol; 2013 Mar; 8(1):47-53. PubMed ID: 23300028
[TBL] [Abstract][Full Text] [Related]
19. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
